这是一篇来自已证抗体库的有关人类 DR5的综述,是根据29篇发表使用所有方法的文章归纳的。这综述旨在帮助来邦网的访客找到最适合DR5 抗体。
DR5 同义词: CD262; DR5; KILLER; KILLER/DR5; TRAIL-R2; TRAILR2; TRICK2; TRICK2A; TRICK2B; TRICKB; ZTNFR9

BioLegend
小鼠 单克隆(DJR2-4 (7-8))
  • 流式细胞仪; 人类; 图 s2g
BioLegend DR5抗体(BioLegend, DJR2-4 (7-8))被用于被用于流式细胞仪在人类样本上 (图 s2g). Cell Death Dis (2019) ncbi
小鼠 单克隆(DJR2-4 (7-8))
  • 流式细胞仪; 人类; 图 1b, 1e
BioLegend DR5抗体(Biolegend, 307408)被用于被用于流式细胞仪在人类样本上 (图 1b, 1e). Front Immunol (2019) ncbi
小鼠 单克隆(DJR2-4 (7-8))
  • 其他; 人类; 500 ug/ml; 图 1
BioLegend DR5抗体(BioLegend, 307402)被用于被用于其他在人类样本上浓度为500 ug/ml (图 1). J Extracell Vesicles (2016) ncbi
小鼠 单克隆(DJR2-4 (7-8))
  • 流式细胞仪; 人类; 图 4
BioLegend DR5抗体(BioLegend, 307405)被用于被用于流式细胞仪在人类样本上 (图 4). PLoS ONE (2015) ncbi
小鼠 单克隆(DJR2-4 (7-8))
  • 流式细胞仪; 人类
BioLegend DR5抗体(Biolegend, DJR2-4)被用于被用于流式细胞仪在人类样本上. Clin Cancer Res (2014) ncbi
圣克鲁斯生物技术
小鼠 单克隆(B-D37)
  • 免疫印迹; 人类; 图 2c
圣克鲁斯生物技术 DR5抗体(Santa Cruz, sc-65314)被用于被用于免疫印迹在人类样本上 (图 2c). Breast Cancer Res (2019) ncbi
小鼠 单克隆(D-6)
  • 免疫印迹; 人类; 图 1c
圣克鲁斯生物技术 DR5抗体(Santa Cruz, sc-166624)被用于被用于免疫印迹在人类样本上 (图 1c). J Biol Chem (2019) ncbi
小鼠 单克隆(D-6)
  • 免疫细胞化学; 人类; 1:200
圣克鲁斯生物技术 DR5抗体(Santa Cruz Biotechnology, SC-166624)被用于被用于免疫细胞化学在人类样本上浓度为1:200. Anticancer Drugs (2014) ncbi
小鼠 单克隆(B-D37)
  • 免疫印迹; 人类
圣克鲁斯生物技术 DR5抗体(Santa Cruz Biotechnology, B-D37)被用于被用于免疫印迹在人类样本上. J Biol Chem (2011) ncbi
安迪生物R&D
小鼠 单克隆(71903)
  • 流式细胞仪; 人类; 图 s7b
安迪生物R&D DR5抗体(R&D, mab631)被用于被用于流式细胞仪在人类样本上 (图 s7b). Cell (2019) ncbi
小鼠 单克隆(71908)
  • 流式细胞仪; 人类; 图 5i
安迪生物R&D DR5抗体(R&D Systems, FAB6311P)被用于被用于流式细胞仪在人类样本上 (图 5i). Mol Cancer Res (2017) ncbi
小鼠 单克隆(71908)
  • 流式细胞仪; 人类; 图 st1
安迪生物R&D DR5抗体(R&D Systems, FAB6311P)被用于被用于流式细胞仪在人类样本上 (图 st1). Exp Cell Res (2016) ncbi
小鼠 单克隆(71908)
  • 免疫组化-石蜡切片; 人类
安迪生物R&D DR5抗体(R&D Systems, MAB6311)被用于被用于免疫组化-石蜡切片在人类样本上. Clin Breast Cancer (2015) ncbi
小鼠 单克隆(71908)
  • 流式细胞仪; 人类; 5 ug/ml
安迪生物R&D DR5抗体(R&D Systems, 71908)被用于被用于流式细胞仪在人类样本上浓度为5 ug/ml. J Biol Chem (2011) ncbi
艾博抗(上海)贸易有限公司
domestic rabbit 单克隆
  • 免疫印迹; 人类; 图 4a
艾博抗(上海)贸易有限公司 DR5抗体(Abcam, ab199357)被用于被用于免疫印迹在人类样本上 (图 4a). Arthritis Res Ther (2020) ncbi
小鼠 单克隆(DR5-01-1)
  • 流式细胞仪; 人类; 图 s5b
艾博抗(上海)贸易有限公司 DR5抗体(Abcam, ab53319)被用于被用于流式细胞仪在人类样本上 (图 s5b). Cell (2019) ncbi
赛默飞世尔
小鼠 单克隆(DJR2-4 (7-8))
  • 流式细胞仪; 人类; 图 4c
赛默飞世尔 DR5抗体(eBioscience, 12-9908-41)被用于被用于流式细胞仪在人类样本上 (图 4c). Cell Death Differ (2019) ncbi
小鼠 单克隆(DJR2-4 (7-8))
  • 流式细胞仪; 人类; 图 s2
赛默飞世尔 DR5抗体(eBioscience, DJR2-4)被用于被用于流式细胞仪在人类样本上 (图 s2). BMC Biotechnol (2016) ncbi
Enzo Life Sciences
小鼠 单克隆(DJR2-4)
  • 流式细胞仪; 人类; 1:100; 图 1
Enzo Life Sciences DR5抗体(Enzo life sciences, ALX-804-914-0100)被用于被用于流式细胞仪在人类样本上浓度为1:100 (图 1). Oncotarget (2016) ncbi
武汉三鹰
domestic rabbit 多克隆
  • 免疫印迹; 人类; 1:1000; 图 3d
武汉三鹰 DR5抗体(Proteintech, 15497-1-AP)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 3d). Biochem Biophys Res Commun (2019) ncbi
赛信通(上海)生物试剂有限公司
domestic rabbit 单克隆(D4E9)
  • 免疫印迹; 人类; 图 2a
赛信通(上海)生物试剂有限公司 DR5抗体(CST, 8074)被用于被用于免疫印迹在人类样本上 (图 2a). Cell Death Dis (2020) ncbi
domestic rabbit 单克隆(D4E9)
  • 免疫印迹; 人类; 1:1000; 图 1s4c
赛信通(上海)生物试剂有限公司 DR5抗体(Cell Signaling Technology, 8074)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 1s4c). elife (2020) ncbi
domestic rabbit 单克隆(D4E9)
  • 免疫印迹; 人类; 图 2a
赛信通(上海)生物试剂有限公司 DR5抗体(Cell Signaling Technology, 8074)被用于被用于免疫印迹在人类样本上 (图 2a). Sci Rep (2017) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 人类; 图 2b
赛信通(上海)生物试剂有限公司 DR5抗体(cell signalling, 3696)被用于被用于免疫印迹在人类样本上 (图 2b). EMBO J (2017) ncbi
domestic rabbit 单克隆(D4E9)
  • 免疫印迹基因敲除验证; 人类; 1:1000; 图 9e
  • 免疫细胞化学; 人类; 1:200; 图 2f
赛信通(上海)生物试剂有限公司 DR5抗体(Cell Signaling, D4E9)被用于被用于免疫印迹基因敲除验证在人类样本上浓度为1:1000 (图 9e) 和 被用于免疫细胞化学在人类样本上浓度为1:200 (图 2f). Mol Cell Biol (2017) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 人类; 图 s1
赛信通(上海)生物试剂有限公司 DR5抗体(cell signalling, 3696)被用于被用于免疫印迹在人类样本上 (图 s1). Mol Cell (2017) ncbi
domestic rabbit 单克隆(D4E9)
  • 免疫印迹; 人类; 图 3a
赛信通(上海)生物试剂有限公司 DR5抗体(Cell Signaling, 8074S)被用于被用于免疫印迹在人类样本上 (图 3a). Antioxid Redox Signal (2017) ncbi
domestic rabbit 单克隆(D4E9)
  • 免疫印迹; 人类; 图 2a
赛信通(上海)生物试剂有限公司 DR5抗体(Cell Signaling, 8074)被用于被用于免疫印迹在人类样本上 (图 2a). Int J Biochem Cell Biol (2017) ncbi
domestic rabbit 多克隆
  • 免疫印迹; 人类; 图 2
赛信通(上海)生物试剂有限公司 DR5抗体(Cell Signaling, 3696)被用于被用于免疫印迹在人类样本上 (图 2). J Biol Chem (2016) ncbi
domestic rabbit 单克隆(D4E9)
  • 免疫印迹; 大鼠
  • 免疫细胞化学; 人类
赛信通(上海)生物试剂有限公司 DR5抗体(Cell Signaling, 8074)被用于被用于免疫印迹在大鼠样本上 和 被用于免疫细胞化学在人类样本上. Toxicol Lett (2015) ncbi
ATCC
小鼠 单克隆
  • 免疫细胞化学; 人类
ATCC DR5抗体(American Type Culture Collection, TIB200)被用于被用于免疫细胞化学在人类样本上. Bone (2006) ncbi
文章列表
  1. Yang X, Guo Q, Feng T, Lu Q, Ge L, Pan J, et al. IL13Rα1 protects against rheumatoid arthritis by combating the apoptotic resistance of fibroblast-like synoviocytes. Arthritis Res Ther. 2020;22:184 pubmed 出版商
  2. Ding B, Yuan F, Damle P, Litovchick L, Drapkin R, Grossman S. CtBP determines ovarian cancer cell fate through repression of death receptors. Cell Death Dis. 2020;11:286 pubmed 出版商
  3. Lam M, Marsters S, Ashkenazi A, Walter P. Misfolded proteins bind and activate death receptor 5 to trigger apoptosis during unresolved endoplasmic reticulum stress. elife. 2020;9: pubmed 出版商
  4. Chollat Namy M, Ben Safta Saadoun T, Haferssas D, Meurice G, Chouaib S, Thiery J. The pharmalogical reactivation of p53 function improves breast tumor cell lysis by granzyme B and NK cells through induction of autophagy. Cell Death Dis. 2019;10:695 pubmed 出版商
  5. Staniek J, Lorenzetti R, Heller B, Janowska I, Schneider P, Unger S, et al. TRAIL-R1 and TRAIL-R2 Mediate TRAIL-Dependent Apoptosis in Activated Primary Human B Lymphocytes. Front Immunol. 2019;10:951 pubmed 出版商
  6. Poondla N, Chandrasekaran A, Heese K, Kim K, Ramakrishna S. CRISPR-mediated upregulation of DR5 and downregulation of cFLIP synergistically sensitize HeLa cells to TRAIL-mediated apoptosis. Biochem Biophys Res Commun. 2019;: pubmed 出版商
  7. Pan L, Fu T, Zhao W, Zhao L, Chen W, Qiu C, et al. Higher-Order Clustering of the Transmembrane Anchor of DR5 Drives Signaling. Cell. 2019;176:1477-1489.e14 pubmed 出版商
  8. Greer Y, Gilbert S, Gril B, Narwal R, Peacock Brooks D, Tice D, et al. MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer. Breast Cancer Res. 2019;21:27 pubmed 出版商
  9. Kim M, Song J, Koh D, Kim J, Hatano M, Jeon B, et al. Reciprocal negative regulation between the tumor suppressor protein p53 and B cell CLL/lymphoma 6 (BCL6) via control of caspase-1 expression. J Biol Chem. 2019;294:299-313 pubmed 出版商
  10. Fauster A, Rebsamen M, Willmann K, César Razquin A, Girardi E, Bigenzahn J, et al. Systematic genetic mapping of necroptosis identifies SLC39A7 as modulator of death receptor trafficking. Cell Death Differ. 2019;26:1138-1155 pubmed 出版商
  11. Zhao L, Zhang B. Doxorubicin induces cardiotoxicity through upregulation of death receptors mediated apoptosis in cardiomyocytes. Sci Rep. 2017;7:44735 pubmed 出版商
  12. Lafont E, Kantari Mimoun C, Dráber P, De Miguel D, Hartwig T, Reichert M, et al. The linear ubiquitin chain assembly complex regulates TRAIL-induced gene activation and cell death. EMBO J. 2017;36:1147-1166 pubmed 出版商
  13. Iurlaro R, Püschel F, León Annicchiarico C, O Connor H, Martin S, Palou Gramón D, et al. Glucose Deprivation Induces ATF4-Mediated Apoptosis through TRAIL Death Receptors. Mol Cell Biol. 2017;37: pubmed 出版商
  14. Hartwig T, Montinaro A, von Karstedt S, Sevko A, Surinova S, Chakravarthy A, et al. The TRAIL-Induced Cancer Secretome Promotes a Tumor-Supportive Immune Microenvironment via CCR2. Mol Cell. 2017;65:730-742.e5 pubmed 出版商
  15. Dimberg L, Towers C, Behbakht K, Hotz T, Kim J, Fosmire S, et al. A Genome-Wide Loss-of-Function Screen Identifies SLC26A2 as a Novel Mediator of TRAIL Resistance. Mol Cancer Res. 2017;15:382-394 pubmed 出版商
  16. Seo B, Min K, Woo S, Choe M, Choi K, Lee Y, et al. Inhibition of Cathepsin S Induces Mitochondrial ROS That Sensitizes TRAIL-Mediated Apoptosis Through p53-Mediated Downregulation of Bcl-2 and c-FLIP. Antioxid Redox Signal. 2017;27:215-233 pubmed 出版商
  17. Park S, Jwa E, Shin S, Ju E, Park I, Pak J, et al. Ibulocydine sensitizes human hepatocellular carcinoma cells to TRAIL-induced apoptosis via calpain-mediated Bax cleavage. Int J Biochem Cell Biol. 2017;83:47-55 pubmed 出版商
  18. Weyhenmeyer B, Noonan J, Würstle M, Lincoln F, Johnston G, Rehm M, et al. Predicting the cell death responsiveness and sensitization of glioma cells to TRAIL and temozolomide. Oncotarget. 2016;7:61295-61311 pubmed 出版商
  19. Belov L, Matic K, Hallal S, Best O, Mulligan S, Christopherson R. Extensive surface protein profiles of extracellular vesicles from cancer cells may provide diagnostic signatures from blood samples. J Extracell Vesicles. 2016;5:25355 pubmed 出版商
  20. Lakschevitz F, Hassanpour S, Rubin A, Fine N, Sun C, Glogauer M. Identification of neutrophil surface marker changes in health and inflammation using high-throughput screening flow cytometry. Exp Cell Res. 2016;342:200-9 pubmed 出版商
  21. Liesche C, Venkatraman L, Aschenbrenner S, Grosse S, Grimm D, Eils R, et al. Death receptor-based enrichment of Cas9-expressing cells. BMC Biotechnol. 2016;16:17 pubmed 出版商
  22. Crowder R, Dicker D, El Deiry W. The Deubiquitinase Inhibitor PR-619 Sensitizes Normal Human Fibroblasts to Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)-mediated Cell Death. J Biol Chem. 2016;291:5960-70 pubmed 出版商
  23. Zhang L, Wang H, Ding K, Xu J. FTY720 induces autophagy-related apoptosis and necroptosis in human glioblastoma cells. Toxicol Lett. 2015;236:43-59 pubmed 出版商
  24. Braun F, Mathur R, Sehgal L, Wilkie Grantham R, Chandra J, Berkova Z, et al. Inhibition of methyltransferases accelerates degradation of cFLIP and sensitizes B-cell lymphoma cells to TRAIL-induced apoptosis. PLoS ONE. 2015;10:e0117994 pubmed 出版商
  25. Sullivan E, Jeha S, Kang G, Cheng C, Rooney B, Holladay M, et al. NK cell genotype and phenotype at diagnosis of acute lymphoblastic leukemia correlate with postinduction residual disease. Clin Cancer Res. 2014;20:5986-94 pubmed 出版商
  26. Labovsky V, Martinez L, Davies K, Garcia Rivello H, Calcagno M, Matas A, et al. Association between ligands and receptors related to the progression of early breast cancer in tumor epithelial and stromal cells. Clin Breast Cancer. 2015;15:e13-21 pubmed 出版商
  27. Lee D, Lee C, Kim D, Ae J, Lee T. Digitoxin sensitizes glioma cells to TRAIL-mediated apoptosis by upregulation of death receptor 5 and downregulation of survivin. Anticancer Drugs. 2014;25:44-52 pubmed 出版商
  28. Moriwaki K, Shinzaki S, Miyoshi E. GDP-mannose-4,6-dehydratase (GMDS) deficiency renders colon cancer cells resistant to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor- and CD95-mediated apoptosis by inhibiting complex II formation. J Biol Chem. 2011;286:43123-33 pubmed 出版商
  29. Wenisch S, Trinkaus K, Hild A, Hose D, Heiss C, Alt V, et al. Immunochemical, ultrastructural and electrophysiological investigations of bone-derived stem cells in the course of neuronal differentiation. Bone. 2006;38:911-21 pubmed